Antipsychotic formulation and one-year rehospitalization of Schizophrenia patients: A population-based cohort study

Shiau Shian Huang, Ching Heng Lin, El Wui Loh, Hsin Yu Yang, Chin Hong Chan, Tsuo Hung Lan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: The authors compared the efficacy of long-acting injectable antipsychotics and oral antipsychotics on rehospitalization rate of community-dwelling patients with schizophrenia who had frequent admissions. Methods: The cohort study of 14,610 patients was conducted by analyzing the Taiwan National Health Research Institutes data. The patients were divided into groups that received oral antipsychotics (risperidone, a different second-generation antipsychotic, or a first-generation antipsychotic) or long-acting injectable antipsychotics (risperidone, haloperidol, or flupenthixol). Results: One-year rehospitalization rates of the final cohort of 10,552 patients were the same for both groups (by long-acting injection, 27.3%; by oral administration, 27.3%). Secondary analysis of groups receiving long-acting injectable medication showed that haloperidol resulted in lower rehospitalization rates (haloperidol, 22.5%; risperidone, 27.1%; and flupenthixol, 29.5%). Patients' characteristics, including age, region, and insurance payments were significantly correlatedwith the risk of relapse (p<.05). Conclusions: Except for injectable haloperidol, long-acting injectable antipsychotics seem not to be superior to oral antipsychotics in reducing rehospitalization.

Original languageEnglish
Pages (from-to)1259-1262
Number of pages4
JournalPsychiatric Services
Volume64
Issue number12
DOIs
Publication statusPublished - Dec 1 2013
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Cohort Studies
Haloperidol
Population
Injections
Risperidone
Flupenthixol
Independent Living
Insurance
Taiwan
Oral Administration
Recurrence
Health

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Antipsychotic formulation and one-year rehospitalization of Schizophrenia patients : A population-based cohort study. / Huang, Shiau Shian; Lin, Ching Heng; Loh, El Wui; Yang, Hsin Yu; Chan, Chin Hong; Lan, Tsuo Hung.

In: Psychiatric Services, Vol. 64, No. 12, 01.12.2013, p. 1259-1262.

Research output: Contribution to journalArticle

Huang, Shiau Shian ; Lin, Ching Heng ; Loh, El Wui ; Yang, Hsin Yu ; Chan, Chin Hong ; Lan, Tsuo Hung. / Antipsychotic formulation and one-year rehospitalization of Schizophrenia patients : A population-based cohort study. In: Psychiatric Services. 2013 ; Vol. 64, No. 12. pp. 1259-1262.
@article{7f5b730879b846bb93c7c24913deab62,
title = "Antipsychotic formulation and one-year rehospitalization of Schizophrenia patients: A population-based cohort study",
abstract = "Objective: The authors compared the efficacy of long-acting injectable antipsychotics and oral antipsychotics on rehospitalization rate of community-dwelling patients with schizophrenia who had frequent admissions. Methods: The cohort study of 14,610 patients was conducted by analyzing the Taiwan National Health Research Institutes data. The patients were divided into groups that received oral antipsychotics (risperidone, a different second-generation antipsychotic, or a first-generation antipsychotic) or long-acting injectable antipsychotics (risperidone, haloperidol, or flupenthixol). Results: One-year rehospitalization rates of the final cohort of 10,552 patients were the same for both groups (by long-acting injection, 27.3{\%}; by oral administration, 27.3{\%}). Secondary analysis of groups receiving long-acting injectable medication showed that haloperidol resulted in lower rehospitalization rates (haloperidol, 22.5{\%}; risperidone, 27.1{\%}; and flupenthixol, 29.5{\%}). Patients' characteristics, including age, region, and insurance payments were significantly correlatedwith the risk of relapse (p<.05). Conclusions: Except for injectable haloperidol, long-acting injectable antipsychotics seem not to be superior to oral antipsychotics in reducing rehospitalization.",
author = "Huang, {Shiau Shian} and Lin, {Ching Heng} and Loh, {El Wui} and Yang, {Hsin Yu} and Chan, {Chin Hong} and Lan, {Tsuo Hung}",
year = "2013",
month = "12",
day = "1",
doi = "10.1176/appi.ps.201200506",
language = "English",
volume = "64",
pages = "1259--1262",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "12",

}

TY - JOUR

T1 - Antipsychotic formulation and one-year rehospitalization of Schizophrenia patients

T2 - A population-based cohort study

AU - Huang, Shiau Shian

AU - Lin, Ching Heng

AU - Loh, El Wui

AU - Yang, Hsin Yu

AU - Chan, Chin Hong

AU - Lan, Tsuo Hung

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Objective: The authors compared the efficacy of long-acting injectable antipsychotics and oral antipsychotics on rehospitalization rate of community-dwelling patients with schizophrenia who had frequent admissions. Methods: The cohort study of 14,610 patients was conducted by analyzing the Taiwan National Health Research Institutes data. The patients were divided into groups that received oral antipsychotics (risperidone, a different second-generation antipsychotic, or a first-generation antipsychotic) or long-acting injectable antipsychotics (risperidone, haloperidol, or flupenthixol). Results: One-year rehospitalization rates of the final cohort of 10,552 patients were the same for both groups (by long-acting injection, 27.3%; by oral administration, 27.3%). Secondary analysis of groups receiving long-acting injectable medication showed that haloperidol resulted in lower rehospitalization rates (haloperidol, 22.5%; risperidone, 27.1%; and flupenthixol, 29.5%). Patients' characteristics, including age, region, and insurance payments were significantly correlatedwith the risk of relapse (p<.05). Conclusions: Except for injectable haloperidol, long-acting injectable antipsychotics seem not to be superior to oral antipsychotics in reducing rehospitalization.

AB - Objective: The authors compared the efficacy of long-acting injectable antipsychotics and oral antipsychotics on rehospitalization rate of community-dwelling patients with schizophrenia who had frequent admissions. Methods: The cohort study of 14,610 patients was conducted by analyzing the Taiwan National Health Research Institutes data. The patients were divided into groups that received oral antipsychotics (risperidone, a different second-generation antipsychotic, or a first-generation antipsychotic) or long-acting injectable antipsychotics (risperidone, haloperidol, or flupenthixol). Results: One-year rehospitalization rates of the final cohort of 10,552 patients were the same for both groups (by long-acting injection, 27.3%; by oral administration, 27.3%). Secondary analysis of groups receiving long-acting injectable medication showed that haloperidol resulted in lower rehospitalization rates (haloperidol, 22.5%; risperidone, 27.1%; and flupenthixol, 29.5%). Patients' characteristics, including age, region, and insurance payments were significantly correlatedwith the risk of relapse (p<.05). Conclusions: Except for injectable haloperidol, long-acting injectable antipsychotics seem not to be superior to oral antipsychotics in reducing rehospitalization.

UR - http://www.scopus.com/inward/record.url?scp=84888864542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888864542&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.201200506

DO - 10.1176/appi.ps.201200506

M3 - Article

C2 - 24292730

AN - SCOPUS:84888864542

VL - 64

SP - 1259

EP - 1262

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 12

ER -